OptiTROP-Lung04研究在EGFR-TKI耐药非小细胞肺癌中的创新价值与临床启示OA
Innovative Value and Clinical Implications of OptiTROP-Lung04 Study in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
抗体药物偶联物(ADC)已成为驱动基因阳性经治晚期非小细胞肺癌(NSCLC)的标准治疗手段之一.芦康沙妥珠单抗(sac-TMT)是一种新型TROP-2靶向ADC,其Ⅲ期临床研究OptiTROP-Lung04首次证实在表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药、EGFR突变晚期NSCLC患者中,芦康沙妥珠单抗单药治疗相比传统含铂化疗可显著延长无进展生存期和总生存期.本文结合已有文献共识与最新研究证据,从分子机制、研究设计、临床意义和安全性管理等方面对该研究进行系统评述,并展望其未来发展方向,以期为晚期NSCLC的精准治疗提供新视角.
Antibody-drug conjugates(ADCs)have emerged as a standard treatment modality for previously treated driver gene-positive advanced non-small cell lung cancer(NSCLC).Sacituzumab tirumotecan(sac-TMT),a novel TROP-2-targeting ADC,has been the focus of the phase Ⅲ clinical trial OptiTROP-Lung04.This trial demonstrated,for the first time,that single-agent sac-TMT significantly improves progression-free survival and overall survival compared with conv-entional platinum-based chemotherapy in patients with epidermal growth factor receptor(EGFR)mutant advanced NSCLC following resistance to EGFR tyrosine kinase inhibitors.This review combines existing consensus from lit-erature with the latest research evidence to systematically analyze OptiTROP-Lung04 from multiple perspectives,including molecular mechanisms,study design,clinical significance,and safety management.Furthermore,it explores future development directions in an effort to provide new insights into precision therapy for advanced NSCLC.
谭左源;钟雨玲;王婧怡;邬麟
410013 长沙,湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院胸内二科||421001 衡阳,南华大学衡阳医学院,湖南省肿瘤医院研究生协作培养基地410013 长沙,湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院胸内二科||421001 衡阳,南华大学衡阳医学院,湖南省肿瘤医院研究生协作培养基地410013 长沙,湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院胸内二科410013 长沙,湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院胸内二科
医药卫生
非小细胞肺癌抗体偶联药物人滋养层细胞表面抗原2
Non-small cell lung cancerAntibody-drug conjugateTROP-2
《肿瘤防治研究》 2026 (5)
325-331,7
国家临床重点专科科研专项(Z2023098)湖南省卫生健康高层次人才重大科研专项(R2023125)湖南省科技创新计划(2023SK4024)湖南省肿瘤医院"科研攀登计划"(ZX2020005-5) National Key Clinical Specialty Scientific Research Project(No.Z2023098)Hunan Provincial Health High-level Talent Scientific Research Project(No.R2023125)Science and Technology Innovation Program of Hunan Province(No.2023SK4024)Hunan Cancer Hospital Climb Plan(No.ZX2020005-5)
评论